Vaxcyte PCVX

Vaxcyte raises $959M

Securities offering

Form
FWP
Filed
Importance
Routine
  1. 7,412,500 shares of common stock offered
  2. $500M in convertible notes due 2032
  3. Net proceeds to fund clinical trials and manufacturing
  4. Underwriters include Goldman Sachs, BofA, Jefferies

Written from the FWP on EDGAR. Check the filing before you rely on it.

Get an email when Vaxcyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.